NUZ.ASX: HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule

HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule

Stock	NUZ.ASX (NUZ.ASX)
Release Time	12 Jun 2026, 9:07 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule

Key Points

129 of 240 participants dosed in Regimen I of the HEALEY ALS Platform Trial
Achievement follows recent expansion of Regimen I from 160 to 240 participants
Recruitment and dosing momentum continues to exceed expectations

Full Summary

Neurizon Therapeutics Limited (ASX: NUZ) announced that the HEALEY ALS Platform Trial evaluating NUZ-001 for ALS treatment has surpassed a 50% dosing milestone, with 129 out of 240 participants dosed in Regimen I. This achievement follows the expansion of Regimen I from 160 to 240 participants, aiming for a larger and more informative dataset. As of June 9, 2026, 167 participants have been assigned to Regimen I, with 78 clinical trial sites activated in the US. The milestone highlights the operational strength and efficiency of the trial network and strong engagement from the ALS community.

Guidance

Last participant dosing in Q2 CY2027, topline results in early Q3 CY2027

Outlook

Neurizon remains well positioned to deliver a robust dataset to support future regulatory, partnering, and commercial opportunities for NUZ-001.